Stryker Corporation - SYK STOCK NEWS

Stryker (SYK) has launched the Monterey AL Interbody System, designed for anterior lumbar interbody fusion (ALIF). This innovative device features Tritanium In-Growth Technology, which mimics cancellous bone and supports bone regeneration. New data shows that stem cells cultivated on Tritanium demonstrated osteogenic activity without the need for growth factors. The system includes advanced design features for surgical accessibility, enabling surgeons to enhance patient outcomes. Stryker aims to showcase this system at upcoming medical conferences in October 2022.

Stryker (NYSE:SYK) plans to hold a conference call on October 31, 2022, at 4:30 p.m. ET to discuss its operating results for Q3 2022, which will be released at 4:05 p.m. that day. Interested participants can register for the call via a provided link, with registration open throughout the event. A simultaneous webcast will also be available on their Investor Relations website. Following the call, a replay will be accessible at specific phone numbers. Stryker is a leading medical technology company impacting over 100 million patients annually.

Stryker announced the launch of its Q Guidance System, the first spine navigation software cleared by the FDA for pediatric patients aged 13 and older. This advanced system integrates a redesigned camera and Spine Guidance Software to enhance surgical planning and navigation for spine applications. The system boasts several features, including a proprietary 4th generation camera and improved image processing capabilities. Stryker aims to expand this technology across various surgical specialties in the future.

Stryker (NYSE:SYK) announced the FDA 510(k) clearance of its OptaBlate bone tumor ablation system, marking a significant addition to its Interventional Spine portfolio. This system, featuring patented microinfusion technology, allows treatment of two vertebral body levels simultaneously and reduces ablation time by three minutes. The OptaBlate aims to address the needs of patients with painful metastatic tumors and will be showcased at the North American Spine Society Annual Meeting on October 12-15, 2022, in Chicago.

Stryker (NYSE:SYK) has launched its Pulse Intelligent Delivery Platform tailored for high-volume foot and ankle surgeries in ambulatory surgery centers (ASCs). This platform will debut at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting in Québec City, Canada, from September 14-17. The offering includes smarter configurations, personalized inventory, and automated service through RFID technology. Additionally, Stryker introduced the Prophecy Footprint tool for enhanced surgical planning, aimed at supporting complex ankle replacement cases.

Stryker (NYSE:SYK) has launched the Gamma4 System, enhancing its 30-year legacy of innovation in intramedullary nailing systems. The Gamma4, designed for treating various femur fractures, features several advancements: the Precision Pin™ reduces skiving by 66%, a new nail design for improved geometry, and an integrated instrument platform. Surgeons emphasize the system's usability and efficiency, highlighting its relevance for hip fracture care. This product aims to streamline surgical workflows and elevate patient outcomes.

Stryker (NYSE:SYK) will participate in the 2022 Wells Fargo Securities Healthcare Conference on September 8, 2022, at 2:35 p.m. Eastern Time. Representing the company will be Glenn Boehnlein, CFO, and Jason Beach, VP of Investor Relations. A simultaneous webcast of the presentation will be available on Stryker's website, where it will be archived for later access. Stryker is recognized as a leading medical technology company, impacting over 100 million patients annually through its innovative products and services.

Stryker (NYSE:SYK) announced a quarterly dividend of $0.695 per share, payable on October 31, 2022, to shareholders of record by September 30, 2022. This marks a 10.3% increase compared to the previous year, while remaining unchanged from the last quarter. Stryker, a leader in medical technology, aims to enhance healthcare outcomes with innovative products and services across various fields, impacting over 100 million patients globally each year.

Stryker (NYSE:SYK) reported second quarter 2022 results showcasing a 4.6% increase in net sales to $4.5 billion and a 6.1% organic net sales growth. The reported operating income margin was 17.2%, while adjusted operating income margin contracted by 220 basis points to 23.7%. Reported EPS rose 11.0% to $1.72, with adjusted EPS of $2.25 remaining stable compared to 2021. Despite supply chain challenges, Stryker anticipates full-year organic net sales growth of 8% to 9%, although foreign exchange impacts may negatively affect earnings.